|
A Study of Amprenavir in Patients with Protease Inhibitor-Related Complications Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about A Study of Amprenavir in Patients with Protease Inhibitor-Related Complications conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. A Study of Amprenavir in Patients with Protease Inhibitor-Related Complications Clinical research trials and A Study of Amprenavir in Patients with Protease Inhibitor-Related Complications medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as A Study of Amprenavir in Patients with Protease Inhibitor-Related Complications. A Study of Amprenavir in Patients with Protease Inhibitor-Related Complications Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study of Amprenavir in Patients with Protease Inhibitor-Related Complications clinical trial. Subjects often receive the most expert healthcare possible for their A Study of Amprenavir in Patients with Protease Inhibitor-Related Complications condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Amprenavir in Patients with Protease Inhibitor-Related Complications  A Study of Amprenavir in Patients with Protease Inhibitor-Related Complications
A Study of Amprenavir in Patients with Protease Inhibitor-Related Complications
For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: The purpose of this study is to see if it is safe and effective to give the protease inhibitor (PI) amprenavir (APV) to patients with fat production and distribution problems associated with other PIs. Protease inhibitors are very effective in treating HIV-1 disease. However, patients who take these drugs often have problems, such as hyperlipidemia (an increased level of fat in the blood) and lipodystrophy (problems with the way fat is produced and distributed in the body). Doctors do not know exactly how PIs are related to these problems. APV has been shown to be safe and effective in lowering plasma viral loads (level of HIV in the blood). APV may be useful for patients who develop complications associated with other PIs.
Details: Protease inhibitors are highly efficacious in the treatment of HIV-1 disease. Current drugs, however, are associated with a high incidence of adverse effects as well as metabolic complications such as lipodystrophy and hyperlipidemia. At the same time, though, a causal relationship linking these complications to the use of protease inhibitors remains to be established. Studies have shown APV to be well tolerated and effective in reducing plasma HIV-1 RNA levels. The safety profile of APV suggests it may offer therapeutic potential in subjects developing intolerance to other protease inhibitors. Patients receive open-label APV plus at least 2 other antiretroviral drugs. Fasting blood samples and patient medication adherence questionnaires are collected at Weeks 12 and 24. Bodily assessments are collected at Day 1 and Weeks 12 and 24. Hematology, serum chemistry, plasma HIV-1 viral load determination and CD4+ cell count measurements are collected at pre-entry and every 12 weeks for the duration of the study.
Eligibility:
Study Type: Interventional, Prevention, Safety Study
Minimum Age/Maximum Age: 13 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - Documented HIV-1 infection. - Two consecutive (at least 4 weeks apart) screening HIV-1 plasma RNA levels less than or equal to 10,000 copies/ml prior to open-label drug administration. - Hyperlipidemia with or without lipodystrophy (Grade 1-4 toxicity for triglycerides or total cholesterol), be intolerant to standard protease inhibitor therapy and, in the judgment of the physician, be unable to construct a viable treatment regimen without APV. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: - Renal failure requiring dialysis. - Hepatic failure. - Serious medical conditions such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction which, in the opinion of the investigator, would compromise the safety of the patient. - Malabsorption syndrome or other gastrointestinal dysfunction, which might interfere with drug absorption or render the patient unable to take oral medication. Concurrent Treatment: Excluded: Concomitant use of another protease inhibitor. Patients with the following prior condition are excluded: Clinically relevant history of pancreatitis or hepatitis within the last 6 months. Prior Treatment: Excluded: Previous treatment with APV. Risk Behavior: Excluded: Patients currently using alcohol or illicit drugs which, in the investigator's opinion, may interfere with the patient's ability to comply with the requirements of the study. Included: Prior treatment with at least one protease inhibitor.
Total Enrollment:
Location and Contact Information:
Glaxo Wellcome Inc
Research Triangle Park, North Carolina, 27709
United States
Additional Information:
Study ID Numbers: 264J; PRO30012
Study Start Date:
Record last reviewed: April 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002417
Other Hiv Infections Studies:
1. A Study of Thymic Humoral Factor (THF gamma 2) in HIV-Infected Patients
2. Effects of Storage on Lactate in Blood Samples
3. A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)
4. A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure
5. Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections
Related Studies:
Other HIV Infections Clinical Trials
Other North Carolina Clinical Trials
Other Research Triangle Park Clinical Trials
A Study of Amprenavir in Patients with Protease Inhibitor-Related Complications
|
|
|
|
|
|
|
|
